Sector News

Vascular to be bought by Teleflex in a $1 billion deal

December 6, 2016
Life sciences

Vascular Solutions Inc. announced Friday a deal to be acquired by Teleflex Inc. in a deal valued at $1 billion.

Under terms of the deal, Teleflex will pay $56 in cash for each Vascular share outstanding, a 1.6% premium to Thursday’s closing price of $55.10, which matched Wednesday’s record close.

The acquisition, which is expected to close in the first half of 2017, will be funded through the proceeds from one or more debt financings. Vascular’s stock, which was still inactive in premarket trade, has run up 60% year to date, while Teleflex shares have rallied 11% and the S&P 500 has gained 7.2%.

By Tom Kilgore

Source: MarketWatch

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”